Nothing Special   »   [go: up one dir, main page]

BR112014005406A2 - composição de vacina e respectivo uso - Google Patents

composição de vacina e respectivo uso

Info

Publication number
BR112014005406A2
BR112014005406A2 BR112014005406A BR112014005406A BR112014005406A2 BR 112014005406 A2 BR112014005406 A2 BR 112014005406A2 BR 112014005406 A BR112014005406 A BR 112014005406A BR 112014005406 A BR112014005406 A BR 112014005406A BR 112014005406 A2 BR112014005406 A2 BR 112014005406A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
vaccine
composition
Prior art date
Application number
BR112014005406A
Other languages
English (en)
Inventor
I Fattom Ali
R Baker James
Hamouda Tarek
Bitko Vira
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Publication of BR112014005406A2 publication Critical patent/BR112014005406A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112014005406A 2011-09-09 2012-09-10 composição de vacina e respectivo uso BR112014005406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533062P 2011-09-09 2011-09-09
PCT/US2012/054395 WO2013036907A1 (en) 2011-09-09 2012-09-10 Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine

Publications (1)

Publication Number Publication Date
BR112014005406A2 true BR112014005406A2 (pt) 2017-03-28

Family

ID=47830025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005406A BR112014005406A2 (pt) 2011-09-09 2012-09-10 composição de vacina e respectivo uso

Country Status (7)

Country Link
US (2) US9561271B2 (pt)
EP (2) EP2753354A4 (pt)
JP (2) JP6460792B2 (pt)
CN (1) CN104093421A (pt)
BR (1) BR112014005406A2 (pt)
CA (1) CA2848163C (pt)
WO (1) WO2013036907A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206996B2 (en) * 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
EP2753354A4 (en) * 2011-09-09 2015-04-15 Nanobio Corp SUBUNIT VACCINE AGAINST NANOEMULSION SYNCYTIAL RESPIRATORY VIRUS (RSV)
JP7158853B2 (ja) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
JP6907227B2 (ja) * 2016-03-23 2021-07-21 インターベット インターナショナル ベー. フェー. Pcv2ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン
WO2018204669A1 (en) * 2017-05-03 2018-11-08 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
JP7317796B2 (ja) * 2017-07-24 2023-07-31 ノババックス,インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CN110833546B (zh) * 2018-08-17 2022-06-28 中国科学院分子细胞科学卓越创新中心 通佐溴胺在治疗胃癌中的用途
JP2022507451A (ja) 2018-11-15 2022-01-18 ブルーウィロー バイオロジクス、インコーポレイテッド 強化された透過性を有するナノエマルジョン組成物
US20230226134A1 (en) 2022-01-19 2023-07-20 Herbert Hightower Alvoecore a Respiratory System Protection Product and Immune System Booster

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5103497A (en) 1989-11-14 1992-04-07 Hicks John W Flying spot endoscope
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
DE69940406D1 (de) 1998-12-17 2009-03-26 Sanofi Pasteur Ltd Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1871349A1 (en) 2005-04-11 2008-01-02 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
WO2008051186A2 (en) 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
EP2152304B1 (en) * 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP2011518184A (ja) 2008-04-18 2011-06-23 ナノバイオ コーポレーション ヘルペスウイルス感染の治療方法
EP2293787A1 (en) 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
WO2009132343A1 (en) 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating onchomycosis
CA2725329C (en) * 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20100226983A1 (en) 2009-01-28 2010-09-09 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
JP6110140B2 (ja) * 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
FR2960546B1 (fr) 2010-05-28 2012-07-13 Saint Gobain Rech Composition adhesive renfermant un polyester insature hydrosoluble ou dispersable dans l'eau et un monomere ethyleniquement insature, et utilisations.
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
WO2013006797A1 (en) * 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
EP2753354A4 (en) * 2011-09-09 2015-04-15 Nanobio Corp SUBUNIT VACCINE AGAINST NANOEMULSION SYNCYTIAL RESPIRATORY VIRUS (RSV)

Also Published As

Publication number Publication date
JP6460792B2 (ja) 2019-01-30
EP2753354A4 (en) 2015-04-15
US10596251B2 (en) 2020-03-24
WO2013036907A1 (en) 2013-03-14
JP2014526471A (ja) 2014-10-06
JP2017206514A (ja) 2017-11-24
JP6615151B2 (ja) 2019-12-04
CN104093421A (zh) 2014-10-08
EP3488863A1 (en) 2019-05-29
CA2848163A1 (en) 2013-03-14
US9561271B2 (en) 2017-02-07
CA2848163C (en) 2020-10-27
US20130064867A1 (en) 2013-03-14
US20170360919A1 (en) 2017-12-21
EP2753354A1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112012021065A2 (pt) artigo de uso descartável
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
BR112013010988A2 (pt) composição fluída e uso
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
CO6930362A2 (es) Compuesto heterocíclico y su uso
BR112014005406A2 (pt) composição de vacina e respectivo uso
BR112014023200A2 (pt) uso de uma composição
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
SMT201700110B (it) Composizione immunogena
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112014016635A8 (pt) composto, composição, e, uso de um composto
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
CO6940436A2 (es) Composicion de control de fitoenfermedades y su uso
CO6781486A2 (es) Compuestos y su uso
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
DK2343051T3 (da) Anti-cancer formulering
BRPI1011036A2 (pt) uso
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]